Key result
Intracerebroventricular captopril and valsartan reduce urine output, BUN, and proteinuria in diabetic rats.
Why the study?
The authors hypothesized that diabetic nephropathy caused by peripheral angiotensin-II may be controlled by brain renin-angiotensin-aldosterone system.
Does intracerebroventricular administration of captopril and valsartan improve renal and metabolic parameters in Wistar rats with alloxan-induced diabetic nephropathy?
Does intracerebroventricular administration of captopril and valsartan improve renal and metabolic parameters in Wistar rats with alloxan-induced diabetic nephropathy?
Central administration of ACE inhibitors and ARBs via ICV demonstrates renoprotective effects in a rat model of diabetic nephropathy, suggesting a role for brain RAAS in modulating peripheral nephropathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in diabetic rats; leaves open whether central RAAS modulates human nephropathy.
The renin-angiotensin-aldosterone system (RAAS) plays a key role in diabetic nephropathy (DN). Angiotensin-II secreted during the RAAS pathway increases nephropathy. It stimulates oxidative stress which can quench nitric oxide. Reduced nitric oxide level aggravates Ang-II-induced vasoconstriction. Ang-II has also emerged as a central mediator of the glomerular hemodynamic changes that are associated with renal injury. Deletion of ACE2 is also noted due to increased Ang-II level which leads to the development of DN. We hypothesize that nephropathy caused by Ang-II in the periphery may be controlled by brain RAAS. ACE inhibitors and ARBs may show the renoprotective effect when administered through ICV without crossing the blood-brain barrier. DN was observed after 8 weeks of diabetes induction through alloxan. Administration of captopril and valsartan once and in combined therapy for 2 weeks, significantly reduced urine output, blood urea nitrogen, total protein in the urine, serum cholesterol, serum creatinine, serum triglycerides, and kidney/body weight ratio as compared to diabetic control rats. Further, combination therapy significantly increased the body weight and serum nitrate level as compared to diabetic control animals. However, increased ACE2 levels in the brain may reduce the sympathetic outflow and might have decreased the peripheral activity of Ang-II which shows beneficial effects in DN.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2023) studied Diabetic nephropathy. Captopril and valsartan (alone and in combination) vs. Diabetic control rats was evaluated on Urine output, blood urea nitrogen, total protein in the urine, serum cholesterol, serum creatinine, serum triglycerides, and kidney/body weight ratio. Intracerebroventricular administration of captopril and valsartan significantly reduced urine output, blood urea nitrogen, and proteinuria compared to diabetic control rats.
Synapse has enriched 10 related papers. Consider them for comparative context: